CLINICAL PHARMACOLOGICAL APPROACH TO THE USE OF DRUGS AFFECTING HEMOSTASIS IN CHILDREN
loading.default
item.page.date
item.page.authors
item.page.journal-title
item.page.journal-issn
item.page.volume-title
item.page.publisher
Scholar Express Journals
item.page.abstract
The paper examines the safety and efficacy of using a domestic hemostatic agent, recombinant activated factor VII, coagulagil VII, and prothrombin complex concentrate, prothromplex-600 (Baxter, Austria), in neonatal and pediatric cardiac surgery. The study included 56 children aged 7 days to 5.5 years, who underwent artificial circulation surgery for congenital heart defects. Clinical and laboratory data indicate that coagulagil VII and prothromplex-600 are effective in stopping bleeding.